【Insights】GLP-1：Amgen’s MariTide Demonstrates 20% Weight Loss

2024-11-28

【Insights】HER2：FDA signs off on Merus' first-in-class NRG1+ cancer drug Bizengri

2024-12-06

【Insights】ROR1：Merck Sharp & Dohme Initiates Phase III Clinical Trial of ROR1 ADC

2024-12-06

【Insights】Merck Enters into Exclusive Global GLP-1：License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist

2024-12-19

【Insights】TL1A:Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

2024-12-19

【Insights】GLP:Eden Unveils the World's First Compounded GLP-1 Rx Gummy

2025-01-10

【Insights】Amgen’s IMDYLLTRA®▼ (tarlatamab) Granted a Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in the United Kingdom

2025-01-17

【Insights】IL-23:FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

2025-01-17

【Insights】TL1A：Teva and Sanofi Announce Duvakitug Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

2025-02-10

【Insights】DLL4 Breakthrough in Cancer Therapy: Tovecimig Shows Promise for Biliary Tract Cancer!

2025-04-17

【Insights】GLP-1:Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug

2025-04-25

【Insights】FDA approves penpulimab-kcqx for non-keratinizing nasopharyngeal carcinoma

2025-04-25

【Insights】FGF21：GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of SLD

2025-05-15

【Insights】cMET：U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression

2025-05-15

【Insights】Genomeditech has officially secured global commercial usage rights for HEK293, Jurkat, and CHO-K1 cell lines

2025-06-03

【Insights】PD-L1xVEGF:BioNTech and BMS Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation BsAb Candidate BNT327 Broadly for Multiple Solid Tumor Types

2025-06-11

【Insights】Amylin:Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial

2025-06-18

【Insights】After the GLP-1, where is the next breakthrough in weight-loss drugs?

2025-06-19

【Insights】TROP2：Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

2025-06-25

【News】会议邀请 | 诚邀您莅临第二十届CACLP 吉满展位号A7-2223

2024-01-08